Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK41959 in Combination With Standard Therapy in MTAP-Deficient Advanced Solid Tumors
NCT07699757Phase 1Not yet recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK41959 in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and solid tumor (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events at 3 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HSK41959
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT07699757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699757.